<?xml version="1.0" encoding="UTF-8"?>
<ref id="B23-vaccines-07-00074">
 <label>23.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>van Gils</surname>
    <given-names>M.J.</given-names>
   </name>
   <name>
    <surname>Bunnik</surname>
    <given-names>E.M.</given-names>
   </name>
   <name>
    <surname>Boeser-Nunnink</surname>
    <given-names>B.D.</given-names>
   </name>
   <name>
    <surname>Burger</surname>
    <given-names>J.A.</given-names>
   </name>
   <name>
    <surname>Terlouw-Klein</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Verwer</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Schuitemaker</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <article-title>Longer V1V2 Region with Increased Number of Potential N-Linked Glycosylation Sites in the HIV-1 Envelope Glycoprotein Protects against HIV-Specific Neutralizing Antibodies</article-title>
  <source>J. Virol.</source>
  <year>2011</year>
  <volume>85</volume>
  <fpage>6986</fpage>
  <lpage>6995</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.00268-11</pub-id>
  <?supplied-pmid 21593147?>
  <pub-id pub-id-type="pmid">21593147</pub-id>
 </element-citation>
</ref>
